Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China

被引：16

作者：

Lai Yue-yun ^{[1
]}

Huang Xiao-jun ^{[1
]}

Cai Zhen ^{[2
]}

Cao Xiang-shan ^{[3
]}

Chen Fang-ping ^{[4
]}

Chen Xie-qun ^{[5
]}

Chen Bao-an ^{[6
]}

Fang Mei-yun ^{[7
]}

Feng Jia-fu ^{[8
]}

Fu Wei-ling ^{[9
]}

Guo Hai-ying ^{[10
]}

Hou Ming ^{[11
]}

Hou Jian ^{[12
]}

Hu Yu ^{[13
]}

Hu Xiao-tong ^{[14
]}

Hu Xiao-mei

Huang Li-qiang ^{[15
]}

Jin Jie ^{[2
]}

Li Jian-yong ^{[16
]}

Li Juan ^{[17
]}

Li Wei ^{[18
]}

Liang Ying-min ^{[19
]}

Liu Ting ^{[20
]}

Liu Qi-fa ^{[21
]}

Liu Yan-hui ^{[22
]}

Mao Ping ^{[23
]}

Ouyang Jian ^{[24
]}

Qiu Lu-gui ^{[25
,26
,27
]}

Qiu Lin ^{[28
]}

Shao Chun-kui ^{[29
]}

Shi Bin ^{[30
]}

Song Yong-ping ^{[31
]}

Sun Zi-min ^{[32
]}

Wang Qi-shan ^{[33
]}

Wang Chun ^{[34
]}

Wang Jian-ming ^{[35
]}

Wang Yun-shan ^{[36
]}

Wang Zhao ^{[37
]}

Wu Jian-bo ^{[38
]}

Wu Yin-xia ^{[39
]}

Xia Rui-xiang ^{[40
]}

Xue Yong-quan ^{[41
]}

Yang Bao-zhen ^{[42
]}

Yang Guang ^{[43
]}

Yang Zheng-lin ^{[44
]}

Yu Li ^{[45
]}

Yuan Zhong ^{[46
]}

Zhang Sheng ^{[47
]}

Zhang Yin ^{[48
]}

Zhao Hong-guo ^{[49
]}

机构：

[1] Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China

[3] Soochow Univ, Dept Hematol, Affiliated Hosp 3, Suzhou 213003, Jiangsu, Peoples R China

[4] Cent S Univ, Dept Hematol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China

[5] Fourth Mil Med Univ, Dept Hematol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China

[6] Southeast Univ, Dept Hematol, Zhongda Hosp, Nanjing 210009, Jiangsu, Peoples R China

[7] Dalian Med Univ, Dept Hematol, Affiliated Hosp 1, Dalian 116011, Liaoning, Peoples R China

[8] Mianyang Cent Hosp, Dept Clin Lab, Mianyang 621000, Sichuan, Peoples R China

[9] Third Mil Med Univ, Southwest Hosp, Dept Clin Lab, Chongqing 400038, Peoples R China

[10] Third Peoples Hosp Chengdu, Dept Hematol, Chengdu 610031, Sichuan, Peoples R China

[11] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan 250012, Shandong, Peoples R China

[12] Changzheng Hosp Shanghai, Dept Hematol, Shanghai 200003, Peoples R China

[13] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Hematol, Wuhan 430022, Hubei, Peoples R China

[14] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Cent Lab, Hangzhou 310016, Zhejiang, Peoples R China

[15] Liaoning Prov Benxi Cent Hosp, Dept Hematol, Benxi 117000, Liaoning, Peoples R China

[16] Jiangsu Prov Hosp, Dept Hematol, Nanjing 210029, Jiangsu, Peoples R China

[17] Zhongshan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510080, Guangdong, Peoples R China

[18] Jilin Univ, Affiliated Hosp 1, Dept Hematol, Changchun 130021, Jilin, Peoples R China

[19] Forth Mil Med Univ, Tangdu Hosp, Dept Hematol, Xian 710038, Shaanxi, Peoples R China

[20] Sichuan Univ, W China Hosp, Dept Hematol, Chengdu 610041, Sichuan, Peoples R China

[21] So Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China

[22] Guangdong Gen Hosp, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China

[23] Guangzhou First Municipal Peoples Hosp, Dept Hematol, Guangzhou 510180, Guangdong, Peoples R China

[24] Nanjing Univ, Gulou Hosp, Dept Hematol, Nanjing 210008, Jiangsu, Peoples R China

[25] Chinese Acad Med Sci, Inst Hematol, Tianjin 300020, Peoples R China

[26] Chinese Acad Med Sci, Hosp Blood Dis, Tianjin 300020, Peoples R China

[27] Peking Union Med Coll, Tianjin 300020, Peoples R China

[28] Harbin First Hosp, Dept Hematol, Harbin 150010, Heilongjiang, Peoples R China

[29] Zhongshan Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou 510530, Guangdong, Peoples R China

[30] Capital Med Univ, Fuxing Hosp, Dept Hematol, Beijing 100045, Peoples R China

[31] Henan Canc Hosp, Dept Hematol, Zhengzhou 450003, Henan, Peoples R China

[32] Anhui Prov Hosp, Dept Hematol, Hefei 230032, Anhui, Peoples R China

[33] Shaanxi Prov Peoples Hosp, Dept Hematol, Xian 710068, Shaanxi, Peoples R China

[34] Shanghai First Peoples Hosp, Dept Hematol, Shanghai 200080, Peoples R China

[35] Changhai Hosp Shanghai, Dept Hematol, Shanghai 200433, Peoples R China

[36] Jinan Cent Hosp, Dept Lab Diag Ctr, Jinan 250013, Shandong, Peoples R China

[37] Beijing Friendship Hosp, Dept Hematol, Beijing 100050, Peoples R China

[38] Wenzhou Med Coll, Affiliated Hosp 1, Dept Hematol, Wenzhou 325000, Zhejiang, Peoples R China

[39] Wuhan Univ Sci & Technol, Tianyou Hosp, Dept Internal Med Neurol, Wuhan 430064, Hubei, Peoples R China

[40] Anhui Med Univ, Affiliated Hosp 1, Dept Hematol, Hefei 230022, Anhui, Peoples R China

[41] Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou 215006, Jiangsu, Peoples R China

[42] Ningxia Med Univ, Affiliated Hosp, Dept Med Expt Ctr, Ningxia 750004, Peoples R China

[43] Foshan First Peoples Hosp, Inst Clin Med, Foshan 528000, Guangdong, Peoples R China

[44] Sichuan Prov Peoples Hosp, Dept Clin Lab Ctr, Chengdu 610072, Sichuan, Peoples R China

[45] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China

[46] Zunyi Med Univ, Affiliated Hosp, Dept Hematol, Zunyi 563003, Guizhou, Peoples R China

[47] Fujian Med Univ, Clin Med Coll 1, Dept Pathol, Fuzhou 350005, Fujian, Peoples R China

[48] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou 450003, Henan, Peoples R China

[49] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Hematol, Qingdao 266003, Shandong, Peoples R China

[50] Lanzhou Univ, Affiliated Hosp 1, Dept Hematol, Lanzhou 730000, Gansu, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2012年 / 125卷 / 15期

关键词：

cytogenetics; multiple myeloma; in situ hybridization; fluorescence; STEM-CELL TRANSPLANTATION; IN-SITU HYBRIDIZATION; P53 GENE DELETION; GENOMIC ABERRATIONS; STAGING SYSTEM; SURVIVAL; T(11/14)(Q13; Q32); PROGRESSION; KARYOTYPE; LEUKEMIA;

D O I：

10.3760/cma.j.issn.0366-6999.2012.15.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Chromosomal abnormalities have been shown to play an important prognostic role in multiple myeloma (MM). Interphase fluorescence in situ hybridization (i-FISH) has been much more effective to identify cytogenetic aberrations in MM than conventional cytogenetic technique (CC). To clearly determine the cytogenetic features of Chinese MM patients and identify their prognostic implications, we designed a multicenter study based on i-FISH including 672 patients from 52 hospitals in China. Methods All 672 patients were systematically screened for the following genomic aberrations: del(13q), IgH rearrangement, del(p53) and 1q21 amplifications. Results The analysis showed that the chromosomal changes were detected in 22.1% patients by CC and in 82.3% patients by i-FISH. The most common abnormalities by CC were chromosome 1 aberrations (48.4%), -13/13q- (37.6%), hyperdiploidy (36.6%), hypodiploidy (30.1%) and IgH rearrangements (23.7%). The most frequent abnormalities by FISH was del(13q), which was found in 60.4% patients, whereas IgH rearrangement, 1q21 amplification and p53 deletions were detected in 57.6%, 49.0% and 34.7% cases, respectively. By statistical analysis, -13/13q- by CC was associated with low level of platelet (P=0.015), hyperdiploidy was associated with low level of serum albumin (P=0.028), and IgH rearrangement by FISH was associated with high level of 82 microglobulin (P=0.019). Moreover, 1q21 amplification and del(p53) by FISH conferred a high incidence of progressive disease (PD) after initial therapy. Metaphase detection of IgH rearrangements and chromosome 1 aberrations concurrently was associated with a short progression free survival (PFS) (P=0.036). No significant prognostic implications of other cytogenetic abnormalities were found associated with overall survival and PFS. Conclusions Chinese MM patients had similar cytogenetic abnormalities compared with the previous reported studies. However, the prognostic significance of FISH aberrations were not clearly determined and further study is required. Chin Med J 2012;125(15):2663-2670

引用

页码：2663 / 2670

页数：8

共 39 条

[1] P53 deletion is not a frequent event in multiple myeloma
Avet-Loiseau, H
Li, JY
Godon, C
Morineau, N
Daviet, A
Harousseau, JL
Facon, T
Bataille, R
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) : 717 - 719
[2] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
Avet-Loiseau, H
Facon, T
Grosbois, B
Magrangeas, F
Rapp, MJ
Harousseau, JL
Minvielle, S
Bataille, R
[J]. BLOOD, 2002, 99 (06) : 2185 - 2191
[3] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Avet-Loiseau, Herve
Attal, Michel
Moreau, Philippe
Charbonnel, Catherine
Garban, Frederic
Hulin, Cyrille
Leyvraz, Serge
Michallet, Mauricette
Yakoub-Agha, Ibrahim
Garderet, Laurent
Marit, Gerald
Michaux, Lucienne
Voillat, Laurent
Renaud, Marc
Grosbois, Bernard
Guillerm, Gaelle
Benboubker, Lotfi
Monconduit, Mathieu
Thieblemont, Catherine
Casassus, Philippe
Caillot, Denis
Stoppa, Anne-Marie
Sotto, Jean-Jacques
Wetterwald, Marc
Dumontet, Charles
Fuzibet, Jean-Gabriel
Azais, Isabelle
Dorvaux, Veronique
Zandecki, Marc
Bataille, Regis
Minvielle, Stephane
Harousseau, Jean-Luc
Facon, Thierry
Mathiot, Claire
[J]. BLOOD, 2007, 109 (08) : 3489 - 3495
[4] Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Avet-Loiseau, Herve
Leleu, Xavier
Roussel, Murielle
Moreau, Philippe
Guerin-Charbonnel, Catherine
Caillot, Denis
Marit, Gerald
Benboubker, Lotfi
Voillat, Laurent
Mathiot, Claire
Kolb, Brigitte
Macro, Margaret
Campion, Loic
Wetterwald, Marc
Stoppa, Anne-Marie
Hulin, Cyrille
Facon, Thierry
Attal, Michel
Minvielle, Stephane
Harousseau, Jean-Luc
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4630 - 4634
[5] p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
Chang, H
Qi, C
Yi, QL
Reece, D
Stewart, AK
[J]. BLOOD, 2005, 105 (01) : 358 - 360
[6] Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains
Chang, Hong
Trieu, Young
Qi, Xiaoying
Jiang, Nan N.
Xu, Wei
Reece, Donna
[J]. LEUKEMIA RESEARCH, 2011, 35 (01) : 95 - 98
[7] DEWALD GW, 1985, BLOOD, V66, P380
[8] Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy
Drach, J
Ackermann, J
Fritz, E
Krömer, E
Schuster, R
Gisslinger, H
DeSantis, M
Zojer, N
Fiegl, M
Roka, S
Schuster, J
Heinz, R
Ludwig, H
Huber, H
[J]. BLOOD, 1998, 92 (03) : 802 - 809
[9] International uniform response criteria for multiple myeloma
Durie, B. G. M.
Harousseau, J-L
Miguel, J. S.
Blade, J.
Barlogie, B.
Anderson, K.
Gertz, M.
Dimopoulos, M.
Westin, J.
Sonneveld, P.
Ludwig, H.
Gahrton, G.
Beksac, M.
Crowley, J.
Belch, A.
Boccadaro, M.
Turesson, I.
Joshua, D.
Vesole, D.
Kyle, R.
Alexanian, R.
Tricot, G.
Attal, M.
Merlini, G.
Powles, R.
Richardson, P.
Shimizu, K.
Tosi, P.
Morgan, G.
Rajkumar, S. V.
[J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
[10] DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO

← 1 2 3 4 →